London – AstraZeneca has announced that its daily pill decreases deaths in lung cancer patients by half. The results were talked about at the American Society of Clinical Oncology in Chicago and published  in the New England Journal of Medicine. The medication, known as osimertinib and marketed as Tagrisso, targets a particular receptor that promotes the growth of cancer cells. …